Diagnosis
Trust awarded £250,000 government funding to launch pioneering endometriosis trial

University Hospitals of North Midlands (UHNM) has secured £250k to trial a dye-based technique in endometriosis surgery aimed at reducing pain and surgical complications.
The two-year ICE trial will compare the use of indocyanine green (ICG) dye with standard ureter stenting, aiming to better protect urinary structures during deep endometriosis procedures.
Funded by the NIHR Research for Patient Benefit Programme, the feasibility study will explore whether this method can improve outcomes, reduce complications, and support recovery.
Mr Gourab Misra, consultant gynaecologist at UHNM and chief investigator, said: “Surgery for deep endometriosis is complex and carries a risk of damaging the ureters, the delicate tubes connecting the kidneys to the bladder.
“Traditionally, surgeons use stents to identify and protect these structures, but these can cause significant pain, bleeding, and require a second procedure to remove.
“As a group of surgeons, we saw the challenges our patients faced and worked hard to design this proposal.
“Our aim is to minimise complications and improve the patient journey, reducing pain and morbidity associated with these complex procedures.”
Endometriosis is a condition where tissue similar to the womb lining grows outside the uterus, often causing chronic pelvic pain and infertility.
In severe cases, surgery may be required, which carries a risk of injuring the ureters—tubes that transport urine from the kidneys to the bladder.
Currently, surgeons often use plastic tubes called stents to protect the ureters during surgery.
These are typically left in for two to four weeks but can cause pain, blood in the urine and require removal through an additional procedure.
The new approach uses a small catheter to deliver ICG dye into the ureters, making them visible under a special light during surgery—potentially avoiding the need for stents.
The trial will recruit 70 patients across UHNM and Birmingham Women’s and Children’s NHS Foundation Trust, with participants randomly assigned to receive either the conventional stent method or the dye-based technique.
It will assess feasibility, including whether patients and surgeons are willing to participate, with the goal of informing a future full-scale trial that could lead to wider adoption across the NHS and internationally.
Professor Justin Clark, consultant gynaecologist leading the study at Birmingham Women’s and Children’s NHS Foundation Trust, said: “Deep endometriosis affects and causes significant pain adversely affecting quality of life.
“Whilst surgery is effective, it is highly complex.
“This trial uses a novel dye called ICG that identifies the ureters, which are pipes that transport urine from the kidney to the bladder.
“We hope that this study will show that using ICG can reduce complications, speed up surgery, and reduce pain following the operation, as well as enhance recovery.”
Diagnosis
WHO launches AI tool for reproductive health information

The World Health Organization (WHO) has launched an AI tool in beta to help policymakers, experts and healthcare professionals access sexual and reproductive health information faster.
Called ChatHRP, the tool was created by WHO’s Human Reproduction Programme and draws only on verified research and guidance collected by HRP and WHO.
It uses natural language processing and retrieval-augmented generation to produce referenced content and cut the time spent searching through documents across different platforms and databases.
WHO said ChatHRP also has multilingual capabilities and low-bandwidth functionality to support use in a wide range of settings.
The beta-testing phase is aimed at a broad professional audience, including policymakers, healthcare workers, researchers and civil society groups.
WHO said the tool can help users quickly access up-to-date evidence, find sources for academic work and verify information on sexual and reproductive health and rights.
Examples of questions it can answer include the latest violence against women data in Oceania for women aged 15 to 49, recommendations on managing diabetes during pregnancy, and whether PrEP and contraception can be used at the same time. PrEP is medicine used to reduce the risk of getting HIV.
WHO added that the system will be updated regularly as new HRP materials are published and includes a feedback loop so users can flag gaps in the information provided.
The launch comes amid wider concern about misinformation in sexual and reproductive health.
A 2025 scoping review found that misinformation in digital spaces is a systemic issue that can undermine human rights, reinforce discriminatory social norms and exclude marginalised voices.
The review also said misinformation can affect health systems by shaping provider knowledge and practice, disrupting service delivery and creating barriers to equitable care.
WHO said ChatHRP is intended to give users streamlined access to reliable information as a counter to “algorithms, opinions, or misinformation”.
Menopause
AI maps how reproductive organs age differently during menopause
Pregnancy
Early miscarriage care could prevent 10,000 pregnancy losses a year, study finds
Entrepreneur1 week agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Fertility3 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Menopause3 weeks agoMore research needed to understand link between brain fog and menopause, expert says
Mental health2 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
Insight3 weeks agoSelf-employment linked to better cardiovascular health outcomes in Hispanic women
Entrepreneur3 weeks agoFlora Fertility closes US$5m seed round
Entrepreneur5 days agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
News2 weeks agoResistance training has preventative effects in menopause, study finds
















